Back to News
Market Impact: 0.18

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

Source: globenewswire.com

Healthcare & BiotechProduct LaunchesCompany Fundamentals
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

HUTCHMED announced an exclusive license for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate (ATTC), with expected clinical trial entry in H2 2026. The update is a forward-looking pipeline milestone that modestly improves the company’s development outlook, but it is not near-term commercial/clinical data.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.25

More News

From AllMind Research

Browse all research